Related Experiment Video
Updated: Jul 13, 2025
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.3K
Treating rare tumors with liver transplantation
Andrew Melehy1, Vatche Agopian
1Dumont-UCLA Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Current Opinion in Organ Transplantation
|October 18, 2023
Summary
Liver transplantation (LT) offers excellent outcomes for select rare cancers like GEP-NETs and HEHE. However, its role in FLC and HAS is less defined, requiring careful patient selection for oncologic indications.
Area of Science:
- Hepatobiliary surgery
- Oncology
- Transplantation medicine
Background:
- Growing success of liver transplantation (LT) for hepatocellular carcinoma (HCC) fuels interest in LT for other oncologic conditions.
- This review explores LT's utility in rare liver malignancies.
Approach:
- Literature review of documented indications for LT in rare oncologic conditions.
- Summarization of LT experience and proposed management guidelines for these indications.
Key Points:
- LT for GEP-NETs with liver metastases shows excellent survival (10-year: 88%) with strict criteria (low grade, Ki-67 < 20%, etc.).
- LT for HEHE offers favorable outcomes (10-year survival ~70%).
- LT for FLC has variable outcomes (5-year survival 50%), while HAS has a poor prognosis even with LT.
Conclusions:
- LT is a viable option for specific rare liver cancers, particularly GEP-NETs and HEHE, when stringent selection criteria are met.
- Management guidelines are proposed to optimize LT outcomes for these rare oncologic indications.
- Further research is needed to clarify LT's role in FLC and HAS.
